Our PR and IR tools are designed to meet all necessary regulatory requirements, giving you the confidence to communicate effectively and compliantly. Streamline your communications needs today with our one-stop shop offering.
Private CompaniesWhether a startup or established brand, we deliver the support, targeted distribution, media outreach, and flexible pricing & payment options needed to amplify your story with confidence.
AgenciesWe simplify the process of delivering success for both you and your clients. We understand the importance of getting it right, equipping you with seamless billing, flexible plans and payment structures, and clear reporting and analytics to ensure every campaign runs smoothly and achieves measurable results.
We understand the need to manage high volume of press release distribution efficiently. That's why we offer a dedicated API designed specifically for our legal customers, delivering a streamlined, simple process that ensures value and ease at every step.
Resellers, Publishers & Market ResearchWe understand the importance of cost efficiency for high-volume partners, which is why we offer bulk discounts tailored to meet your needs while maximizing value.
UPPSALA, SWEDEN / ACCESSWIRE / May 9, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer diagnostics, today announces that the company's blood test DiviTum®TKa will be included in one oral presentation and two abstracts/posters, at the world's largest cancer congress, ASCO Annual Meeting, June 3-7, 2022, in Chicago, USA. Results from BioItaLEE, an Italian multicenter study of metastatic BC, CDK4/6...
Read more
SAN DIEGO, CA / ACCESSWIRE / May 5, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today announced the release of its 2021 Annual Shareholder Letter authored by Chief Executive Officer, Dr. Lynn Kirkpatrick. To view the letter...
Read more
The licensed technology was jointly invented by researchers at Case Western Reserve University and Dartmouth College The license covers the use of plant viruses such as cowpea mosaic virus (CPMV) for the treatment of cancer in both human and companion animals NOVATO, CA / ACCESSWIRE / May 5, 2022 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology...
Read more
VERO BEACH, FL / ACCESSWIRE / May 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers, is pleased to announce that its CEO, Sean Carrick, was recently interviewed by Proactive Investors (ProactiveInvestors.com), providing a brief history of Nascent Biotech as well as fresh...
Read more
BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2022 investor call on Wednesday, May 11, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access...
Read morePARIS, FRANCE / ACCESSWIRE / May 4, 2022 / The HealthTech Innovation Days (HTID®) event, held by the HealthTech For Care endowment fund, will take place on 13th and 14th October 2022 and will provide a forum for promising European life sciences companies to accelerate their growth and bring their solutions to patients more quickly. The 4th edition will take place in a hybrid format, in Paris, in the HealthTech space, and in virtual mode. The...
Read more
Global revenue grew 20% year-over-year as adoption increased across all product lines AUSTIN, TX / ACCESSWIRE / May 3, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the first quarter ended March 31, 2022 and recent corporate highlights. First Quarter 2022 Selected Financial Results (Numbers in...
Read more
NASHVILLE, TN / ACCESSWIRE / May 3, 2022 / Thermic Science International Corporation, (OTC:ENDO), a U.S. an Advanced Technology Global Consortium, focused on providing key real-time, public access Digital HUB with advanced SaaS solutions. Focused on a hybrid mix of traditional real-world transactions online with real-time inter-connectivity tools for business and personal information and transactions. Thermic Science is pleased to report an...
Read moreNewly created position to spearhead technological innovation in the next stage of growth ESCONDIDO, CA / ACCESSWIRE / May 3, 2022 / CB Scientific. Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products and services, today announces that effectively immediately James Ott has joined the Company's executive management team as its Chief Technology Officer. Mr. Ott...
Read more
LUND, SWEDEN / ACCESSWIRE / May 3, 2022 / BioInvent International (STO:BINV) BI-1206 moving into expansion phase as planned Data presented so far include early signs of efficacy Next steps to include planning potentially pivotal Phase 2 study Lund, Sweden - May 3, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...
Read more
- Ended the quarter with $51.3 million in cash - expected to fund operations through the end of 2024 including release of topline pivotal trial data - Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll patients - Progress on development of second device for the treatment of venous disease expected to be unveiled in mid-2022 IRVINE, CA / ACCESSWIRE / May 2, 2022 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno"...
Read moreVANCOUVER, BC / ACCESSWIRE / April 30, 2022 / HAVN Life Sciences Inc. (CSE:HAVN) (OTC:HAVLF) (FSE:5NP), a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, today announced that it will be presenting at the Planet MicroCap Showcase 2022 at the Bally's Hotel & Casino in Las Vegas, NV on Wednesday, May 4, 2022 at 9:00 a.m....
Read more
UPPSALA, SE / ACCESSWIRE / April 28, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer diagnostics, today announces that the company has submitted its updated 510(k)-application to the U.S. Food and Drug Administration (FDA) to receive marketing authorization for the blood-based biomarker assay DiviTum®TKa. Biovica's complete submission addresses the deficiencies identified by the agency on Biovica's...
Read more
LUND, SWEDEN / ACCESSWIRE / April 28, 2022 / BioInvent International (STO:BINV) The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) resolved to re-elect the Board members Kristoffer Bissessar, Dharminder Chahal, Thomas Hecht, Leonard Kruimer, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program. The AGM voted in favor of adopting the income statements and balance...
Read more
Completion of enrollment is anticipated by calendar fourth quarter for the Phase 2b study of Edesa's potentially first-in-class, anti-inflammatory drug TORONTO, ON / ACCESSWIRE / April 28, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that patient recruitment for a Phase 2b clinical study evaluating the company's drug candidate, designated...
Read more
LUND, SWEDEN / ACCESSWIRE / April 28, 2022 / BioInvent International (STO:BINV) Lund, Sweden - April 28, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces that it receives a milestone payment following clinical progression of an out-licensed antibody. BioInvent receives...
Read more
UPPSALA, SWEDEN / ACCESSWIRE / April 28, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer diagnostics, will host a Capital Markets Day on Tuesday May 17, 2022, from 14.00 to 16.30. Biovica is approaching market launch of DiviTum®TKa in the US for the monitoring of metastatic breast cancer treatments. Today, DiviTum®TKa is sold to pharmaceutical companies and academic institutions for use in clinical...
Read more
Strong Market Demand Fuels Company's Decision to Access Early Revenue Generating Opportunities for UST Processing of High Quality Nanoemulsions of Oil-Based Active Ingredients for Multiple Markets Ahead of Q4 2022 Commercialization - Company Expects Several Executed Contracts During Q2 2022 SOUTH EASTON, MA / ACCESSWIRE / April 27, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of...
Read more
Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunity DNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications Xenetic plans to conduct a Phase 1 clinical study of lead asset in locally advanced or metastatic solid tumors Company to host update conference call and...
Read more
LUND, SE / ACCESSWIRE / April 27, 2022 / BioInvent International (STO:BINV) "The exciting translational data presented on BI-1808 at AACR clearly show why we are so enthusiastic about our ongoing clinical studies in solid tumors. It is highly encouraging that we see similar biomarker correlations in patient samples as we observe in the preclinical setting."- Martin Welschof, CEO BioInvent. EVENTS IN THE FIRST QUARTER • (R) Orphan Drug...
Read more
